Tonix Pharmaceuticals Holding Corp. Balance Sheet
TNXP|3 years of annual SEC 10-K data (FY2023-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Total Assets
$277M
FY2025
Cash
$208M
Cash and equivalents
Total Debt
N/A
FY2025
Shareholder Equity
$140M
FY2025
Tonix Pharmaceuticals Holding Corp. had $277M in total assets and $140M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash & Equivalents | $207.6M | $98.8M | $24.9M |
| Accounts Receivable | $6.3M | $3.7M | - |
| Inventory | $2.1M | $5.1M | $13.6M |
| Current Assets | $228.9M | $119.0M | $47.8M |
| PP&E (Net) | $44.5M | $42.3M | $94.0M |
| Goodwill | - | - | $965.0K |
| Total Assets | $277.2M | $162.9M | $154.5M |
| Current Liabilities | $30.8M | $18.3M | $18.9M |
| Total Debt | - | $8.7M | $11.0M |
| Shareholders' Equity | $139.6M | $105.5M | $207.2M |